Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

DOI: https://doi.org/10.58347/tml.2024.1700a

2024-04-15

Abstract:The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication.

pharmacology & pharmacy

What problem does this paper attempt to address?

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

Andrew Blauvelt,Zoe D. Draelos,Linda Stein Gold,Javier Alonso-Llamazares,Neal Bhatia,Janet DuBois,Seth B. Forman,Melinda Gooderham,Lawrence Green,Scott T. Guenthner,Adelaide A. Hebert,Edward Lain,Angela Y. Moore,Kim A. Papp,Matthew Zirwas,Saori Kato,Scott Snyder,David Krupa,Patrick Burnett,David R. Berk,David H. Chu

DOI: https://doi.org/10.1016/j.jaad.2023.12.065

IF: 15.487

2024-01-22

Journal of the American Academy of Dermatology

Abstract:Background The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. Objective Roflumilast foam 0.3% is being investigated as a topical treatment for seborrheic dermatitis (SD). Methods In this phase 3, double-blinded trial, patients with SD were randomly assigned (2:1 ratio) to once-daily roflumilast foam 0.3% or vehicle foam for 8 weeks. The primary efficacy outcome was Investigator Global Assessment (IGA) Success at week 8, defined as IGA of 0 (Clear) or 1 (Almost Clear) plus ≥2-point improvement from baseline. Safety was also assessed. Results 79.5% of roflumilast-treated and 58.0% of vehicle-treated patients met the primary endpoint ( P < .001); statistically significant differences in IGA Success also favored roflumilast at week 2 (roflumilast: 43.0%; vehicle: 25.7%; P < .001) and week 4 (roflumilast: 73.1%; vehicle: 47.1%; P < .001). Roflumilast was well-tolerated with a low rate of treatment-emergent adverse events. Limitations Study limitations include the 8-week treatment period for this chronic condition. Conclusions Once-daily roflumilast foam was superior to vehicle in leading to IGA of Clear or Almost Clear plus ≥2-point improvement from baseline at 8 weeks in patients with SD. Longer trials are needed to determine durability and safety of roflumilast foam in SD.

dermatology
Research progress of roflumilast in the treatment of chronic obstructive pulmonary disease

Lin TONG,Hui-fang TANG

DOI: https://doi.org/10.13683/j.wph.2017.04.014

2017-01-01

Abstract:Chronic obstructive pulmonary disease (COPD) is a common disease characterized by persistent and progressive airflow limitation,which increases chronic inflammatory response in the airway with acute exacerbation and complications.Roflumilast is the only phosphodiesterase-4 inhibitor that can be oral administration for the treatment of COPD approved by the EU and FDA.Roflumilast has a strong anti-inflammatory effect and moderate bronchial dilatation,which can effectively improve lung function,and significantly reduce the deterioration in moderate and severe COPD patients,to prevent from acute exacerbations.This review summarizes the advances of roflurnilast in the clinical treatment of COPD.
639 - Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial

Lawrence Eichenfield,John Browning,Tracy Funk,Mercedes E Gonzalez,Adelaide A Hebert,Mark Lee,Vimal H Prajapati,Rocco Serrao,Lisa Swanson,Robert Higham,David Berk

DOI: https://doi.org/10.1093/bjd/ljae266.020

IF: 11.113

2024-08-01

British Journal of Dermatology

Abstract:Abstract Background Roflumilast is a highly potent phosphodiesterase 4 inhibitor under investigation as a non-steroidal, once-daily cream for atopic dermatitis (AD). Methods INTEGUMENT-PED (NCT04845620) was a Phase 3 parallel-group, double-blind, vehicle-controlled trial. Children aged 2 to 5 years with mild to moderate AD were treated with roflumilast cream 0.05% (n=437) or vehicle (n=215) once-daily for 4 weeks. The primary efficacy endpoint was validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Success (defined as a score of 0 [clear] or 1 [almost clear] with 2-grade improvement from baseline) at Week 4. Secondary endpoints included 75% improvement in Eczema Area and Severity Index (EASI-75). Worst-Itch-Numeric Rating Score (WI-NRS) Success (≥4-point improvement in patients with baseline ≥4), safety, and tolerability were also assessed. Results At Week 4, significantly more roflumilast-treated than vehicle-treated patients achieved vIGA-AD Success (25.4% vs 10.7%; P<0.0001), EASI-75 (39.4% vs 20.6%; P<0.0001), and WI-NRS Success (35.3% vs 18.0%; nominal P=0.0002). Improvement in pruritus was observed by 24 hours after first application (nominal P=0.0014 versus vehicle). Incidence of treatment-emergent adverse events (AEs) was low in both arms, with 98.9% assessed as mild to moderate. AEs occurring in >2% of patients and greater in the roflumilast-treated group were upper respiratory tract infection, diarrhea, and vomiting. For local tolerability, >92% of roflumilast-treated patients reported no or mild sensation across arms at any timepoint. Conclusion In this phase 3 trial, once-daily roflumilast cream 0.05% improved AD in pediatric patients (2 to 5 years of age), while demonstrating favorable safety and tolerability.

dermatology
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials

Eric L Simpson,Lawrence F Eichenfield,Javier Alonso-Llamazares,Zoe D Draelos,Laura K Ferris,Seth B Forman,Melinda Gooderham,Mercedes E Gonzalez,Adelaide A Hebert,Leon H Kircik,Mark Lomaga,Angela Moore,Kim A Papp,Vimal H Prajapati,Diane Hanna,Scott Snyder,David Krupa,Patrick Burnett,Erin Almaraz,Robert C Higham,David H Chu,David R Berk

DOI: https://doi.org/10.1001/jamadermatol.2024.3121

2024-09-18

Abstract:Importance: Safe, effective, and well-tolerated topical treatment options available for long-term use in patients with atopic dermatitis (AD) are limited and associated with low adherence rates. Objective: To evaluate efficacy and safety of once-daily roflumilast cream, 0.15%, vs vehicle cream in patients with AD. Design, setting, and participants: Two phase 3, randomized, double-blind, vehicle-controlled trials (Interventional Trial Evaluating Roflumilast Cream for the Treatment of Atopic Dermatitis 1 and 2 [INTEGUMENT-1 and INTEGUMENT-2]), included patients from sites in the US, Canada, and Poland. Participants were 6 years or older with mild to moderate AD based on Validated Global Assessment for Atopic Dermatitis (assessed on a 5-point scale ranging from 0 [clear] to 4 [severe]). Intervention: Patients were randomized 2:1 to receive roflumilast cream, 0.15%, or vehicle cream once daily for 4 weeks. Main outcomes and measures: The primary efficacy end point was Validated Investigator Global Assessment for Atopic Dermatitis success at week 4, defined as a score of 0 or 1 plus at least a 2-grade improvement from baseline. Secondary end points included Eczema Area and Severity Index and Worst Itch Numeric Rating Scale. Safety and local tolerability were also evaluated. Results: Among 1337 patients (654 patients in INTEGUMENT-1 and 683 patients in INTEGUMENT-2), the mean (SD) age was 27.7 (19.2) years, and 761 participants (56.9%) were female. The mean body surface area involved was 13.6% (SD = 11.6%; range, 3.0% to 88.0%). Significantly more patients treated with roflumilast than vehicle achieved the primary end point (INTEGUMENT-1: 32.0% vs 15.2%, respectively; P < .001; INTEGUMENT-2: 28.9% vs 12.0%, respectively; P < .001). At week 4, statistically significant differences favoring roflumilast also occurred for the achievement of at least 75% reduction in the Eczema Area and Severity Index (INTEGUMENT-1: 43.2% vs 22.0%, respectively; P < .001; INTEGUMENT-2: 42.0% vs 19.7%, respectively; P < .001). Roflumilast was well tolerated with low rates of treatment-emergent adverse events. At each time point, investigators noted no signs of irritation at the application site in 885 patients who were treated with roflumilast (≥95%), and 885 patients who were treated with roflumilast (90%) reported no or mild sensation at the application site. Conclusions and relevance: In 2 phase 3 trials enrolling adults and children, once-daily roflumilast cream, 0.15%, improved AD relative to vehicle cream, based on multiple efficacy end points, with favorable safety and tolerability. Trial registration: ClinicalTrials.gov Identifiers: NCT04773587, NCT04773600.
Successful Treatment of Seborrheic Dermatitis with Topical Roflumilast: A Case Series

Ciaran Smythe,Alice Sohn,Eingun James Song,George Michael Lewitt

DOI: https://doi.org/10.25251/skin.8.5.20

2024-09-15

SKIN The Journal of Cutaneous Medicine

Abstract:Background: Seborrheic dermatitis (SD) is a common skin disease that presents with pink scaly patches in areas with higher sebaceous gland density, such as the scalp, glabella, retroauricular folds, nasolabial folds, chest, and groin. Case Reports: This is a case series of two patients with longstanding SD that did not respond adequately to topical corticosteroids or azoles, and were successfully treated monotherapy with roflumilast cream 0.3%. Both patients responded within two months and continue to respond to treatment with topical roflumilast monotherapy. Discussion: SD is commonly considered to be caused by Malassezia yeast proliferation and activity, however recent research has revealed that the inflammatory skin disease results from immune dysregulation and skin barrier disruption with Malassezia contributing as an exacerbating factor secondary to the primary pathogenesis. Thus treatment with topical roflumilast, a highly potent phosphodiesterase-4 inhibitor, has been studied and demonstrated to be effective in treating the signs and symptoms of SD. Topical roflumilast 0.3% is formulated as a cream and a foam, with the foam approved for the treatment of SD. These cases demonstrate a successful treatment of patients with longstanding SD with roflumilast cream 0.3%. Conclusion: These cases demonstrate that SD, treated with either roflumilast cream 0.3% or roflumilast foam 0.3% may provide improvement in signs and symptoms of SD.
505 - Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials

Lawrence F Eichenfield,Mark Boguniewicz,Eric L Simpson,Andrew Blauvelt,Melinda Gooderham,Edward Lain,David H Chu,Robert C Higham

DOI: https://doi.org/10.1093/bjd/ljad498.013

IF: 11.113

2024-02-01

British Journal of Dermatology

Abstract:Abstract Introduction Roflumilast cream 0.15% is a selective, highly potent phosphodiesterase 4 inhibitor under investigation as a non-steroidal, once-daily treatment for atopic dermatitis (AD). Objectives Here, pooled results from two identical Phase 3 randomized controlled trials (INTEGUMENT-1: NCT04773587 and INTEGUMENT-2: NCT04773600) are presented. Methods Patients with AD aged ≥6 years with baseline Eczema Area and Severity Index (EASI) score ≥5 and Validated Investigator Global Assessment-AD (vIGA-AD) score of Mild or Moderate were randomized 2:1 to apply roflumilast (n=884) or vehicle (n=453) once daily for 4 weeks. Results A significantly greater percentage of roflumilast- versus vehicle-treated patients achieved the primary endpoint, vIGA-AD Success (Clear or Almost Clear vIGA-AD plus ≥2-grade improvement from baseline) at Week 4 (31.3% vs. 14.1%; P<0.0001). Significant differences favoring roflumilast were observed for multiple secondary endpoints at Week 4: percentage of patients achieving vIGA-AD of Clear or Almost Clear (41.1% vs. 21.4%; P<0.0001), percentage achieving 75% reduction in EASI (42.7% vs. 20.6%; P<0.0001), and percentage with baseline Worst Itch-Numeric Rating Scale ≥4 achieving a 4-point reduction (31.9% vs. 16.6%; P<0.0001). Improvement in itch was reported as early as 24 hours. Both groups had low incidences of treatment-emergent adverse events (TEAE), serious adverse events, and TEAEs leading to discontinuation. Local tolerability was favorable, with >90% of patients reporting no or mild sensation across both treatment groups at all timepoints. Conclusions Once-daily roflumilast cream 0.15% provided improvement across multiple efficacy endpoints by Week 4 with favorable safety and tolerability in patients aged ≥6 years with AD in two Phase 3 trials.

dermatology
504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis

Christopher G Bunick,Neal Bhatia,James Del Rosso,Zoe D Draelos,Lawrence F Eichenfield,Leon H Kircik,Mark G Lebwohl,Melinda Gooderham,Lawrence J Green,Adelaide A Hebert,Ronald B Vender,Matthew Zirwas,Eric L Simpson,Linda Stein Gold,Melissa Seal,Scott Snyder,David W Osborne,Patrick Burnett,Robert C Higham,David H Chu,David R Berk,James Del Rosso,Lawrence F Eichenfield,Mark G Lebwohl,Ronald B Vender,Eric L Simpson,Linda Stein Gold,Robert C Higham,David R Berk

DOI: https://doi.org/10.1093/bjd/ljad498.012

IF: 11.113

2024-02-01

British Journal of Dermatology

Abstract:Abstract Introduction Formulating a topical medication that does not irritate the skin is an important factor contributing to patient treatment adherence and satisfaction. Many topical prescription products use penetration enhancers (including propylene glycol, polyethylene glycol, and ethanol) to overcome barrier properties of the skin. However, these excipients may irritate the skin causing tolerability reactions such as burning and stinging, which can reduce patient treatment adherence. Topical roflumilast is a highly potent (Kd∼0.7 nM) phosphodiesterase 4 inhibitor formulated as a water-based cream or foam that does not contain penetration enhancers or fragrances. Objectives We present prospectively assessed investigator- and patient-rated local tolerability from Phase 3 trials of topical roflumilast for patients with psoriasis (DERMIS-1, DERMIS-2, ARRECTOR) seborrheic dermatitis (SD; STRATUM), and atopic dermatitis (AD; INTEGUMENT-1, INTEGUMENT-2). Methods Patients were randomized to apply topical roflumilast (DERMIS: 0.3% cream; ARRECTOR and STRATUM: 0.3% foam; INTEGUMENT: 0.15% cream) or vehicle once daily for 8 weeks (DERMIS, ARRECTOR, and STRATUM) or 4 weeks (INTEGUMENT). Investigators assessed local tolerability on an 8-point scale (0 [no evidence of irritation] to 7 [strong reaction spreading beyond application site]) in the clinic before investigational product (IP) application. Patients reported local tolerability on a 4-point scale (0 [none: no sensation] to 3 [severe: hot, tingling/stinging sensation that has caused definite discomfort]) in the clinic 10-15 minutes after IP application. Tolerability was also assessed by reviewing documented adverse events. Results As assessed by investigators, ≥96.5% of patients in the roflumilast-treated groups had no evidence of irritation at the application site across all trials at all timepoints. Patient-rated local tolerability was favorable and improved with treatment: across all trials, 1% of roflumilast-treated patients reported a score of 3 (severe; defined as a “hot tingling/stinging sensation that has caused definite discomfort”) after the first application (day 1) and <1% at each subsequent assessment. Rates of adverse events, including those at the application site, were low for all trials. Conclusions Roflumilast cream and foam formulations demonstrated favorable local tolerability based on investigator- and patient-rated assessments in patients with psoriasis, SD, and AD, including application to sensitive areas such as the face and intertriginous areas. ClinicalTrials.gov Identifiers: DERMIS-1: NCT04211363; DERMIS-2: NCT04211389; ARRECTOR: NCT05028582; STRATUM: NCT04973228; INTEGUMENT-1: NCT04773587; INTEGUMENT-2: NCT04773600.

dermatology
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)

Mette Gyldenløve,Howraman Meteran,Jennifer A Sørensen,Simon Fage,Yiqiu Yao,Jesper Lindhardsen,Christoffer V Nissen,Tanja Todberg,Simon F Thomsen,Lone Skov,Claus Zachariae,Lars Iversen,Mia-Louise Nielsen,Alexander Egeberg

DOI: https://doi.org/10.1016/j.lanepe.2023.100639

2023-04-21

Abstract:Background: Roflumilast is a targeted inhibitor of phosphodiesterase (PDE)-4 and has been approved for treatment of severe chronic obstructive pulmonary disease for more than a decade. Generic versions are available in the United States. PDE-4 is involved in the psoriasis pathogenesis, but the efficacy and safety of oral roflumilast in patients with psoriasis have not previously been studied. Methods: A company-independent, multicenter, randomized, double-blind, placebo-controlled trial (ClinicalTrials.govNCT04549870). Patients were randomized 1:1 to receive monotherapy with oral roflumilast 500 μg once daily or placebo. At week 12, placebo patients were switched to open-label roflumilast through week 24. The primary endpoint was a 75% or greater reduction from baseline in the psoriasis area and severity index (PASI75) at week 12. Findings: In all, 46 patients were randomized (roflumilast, n = 23; placebo, n = 23). At week 12, significantly more patients in the active arm achieved PASI75 (8 of 23 patients [35%]) vs. placebo (0 of 23 patients [0%], with a difference vs. placebo of 8 [35%] patients, 95% CI: 3 [13%]-13 [57%] patients) (p = 0.014). At week 24, 15 (65%), 10 (44%), 5 (22%), and 2 (9%) of patients treated with roflumilast from week 0 had PASI50, PASI75, PASI90, and PASI100 responses (key secondary endpoints), respectively. The most prevalent, drug-related adverse events in both treatment groups were transient gastrointestinal symptoms, weight-loss, headache, and insomnia. A total of three patients (roflumilast n = 2; placebo, n = 1) discontinued therapy due to adverse events. Interpretation: Oral roflumilast was efficacious and safe in treating moderate-to-severe plaque psoriasis over 24 weeks. With generic versions available, this drug may represent an inexpensive and convenient alternative to established systemic psoriasis treatments. Funding: Financial support was received from Herlev and Gentofte Hospital, University of Copenhagen, and independent grants from private foundations in Denmark. No pharmaceutical company, including the market authorization holder of roflumilast, was involved in the study at any point.
Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors

Jimin Wang,Minh Ho,Christopher G. Bunick

DOI: https://doi.org/10.1016/j.jid.2024.10.597

IF: 7.59

2024-11-30

Journal of Investigative Dermatology

Abstract:Roflumilast, the third phosphodiesterase-IV (PDE4) inhibitor approved for use in dermatology, is indicated for topical treatment of psoriasis, seborrheic dermatitis, and atopic dermatitis, whereas its two predecessors, apremilast and crisaborole, are indicated for oral treatment of psoriasis and topical treatment of atopic dermatitis, respectively. All three are rationally designed PDE4 inhibitors, but roflumilast is the most potent and effective among the three with in vitro inhibitory constant...

dermatology
Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

de Moraes-Souza, Rafaela,Chahine Chater, Regina,Pera Calvi, Izabela,Mesquita, Yasmin,Sarto, Rubiana,Lapenda, Izadora,Figueiredo Pereira, Lívia,Moury, Luana,Herranz-Pinto, Pedro

DOI: https://doi.org/10.1007/s40261-024-01368-w

2024-08-25

Clinical Drug Investigation

Abstract:Plaque psoriasis is commonly treated topically with glucocorticoids and vitamin D derivatives. However, potential side effects such as skin atrophy underscore the need for safe and effective alternative topical therapies. Recently, the US Food and Drug Administration (FDA) and Health Canada approved roflumilast 0.3% cream as an option for treating this disease. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical roflumilast 0.3% compared with vehicle for plaque psoriasis.

pharmacology & pharmacy
P099 Use of roflumilast in erosive oral inflammatory conditions

Rachel Botrugno,Bijaya Rajlawat,Daniel Finn,Paul Devakar Yesudian

DOI: https://doi.org/10.1093/bjd/ljae090.126

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Roflumilast is a phosphodiesterase type 4 (PDE4) inhibitor commonly used in respiratory medicine to manage chronic obstructive lung disease. Recently, there have been case reports of its effectiveness in oral mucosal conditions. We review five patients with different erosive mucosal lesions who responded to this medication. All patients were commenced on 250 μg daily, increasing to 500 μg if indicated. Case 1 is a 57-year-old woman who presented to the dermatology/oral medicine (DOM) clinic with long-standing recurrent aphthous stomatitis from her late teens. Treatment with colchicine and dapsone in combination was ineffective. Roflumilast was added and colchicine was stopped following a positive response. Case 2 is a 78-year-old woman seen in DOM in 2021 with erosive oral lichen planus. She did not respond to oral hydroxychloroquine, mycophenolate mofetil, azathioprine and multiple tapering courses of systemic steroids. Roflumilast was commenced recently, and the patient has not reported any flares since. Case 3 is a 26-year-old man with recurrent erythema multiforme predominantly involving the oral mucosa with erosive changes. He was treated with dapsone, prophylactic valaciclovir, and multiple courses of tapering prednisolone. Response was noted but breakthrough flares continued to occur. Roflumilast was commenced 6 months ago with no flares noted since. Case 4 is a 67-year-old woman who presented to dermatology in 2022 with severe oral erosive lichen planus of 4 years’ duration. Treatment with courses of oral prednisolone, hydroxychloroquine and acitretin were ineffective. Roflumilast was introduced, with excellent remission of all the erosions for the last 7 months. Case 5 is a 34-year-old woman who presented to DOM in August 2021 with recurrent deep, severe aphthous stomatitis. She was previously prescribed mycophenolate mofetil and reducing oral systemic steroids by dermatology for severe pyoderma gangrenosum; however, it did not help the oral ulcers. Hydroxychloroquine, colchicine and azathioprine were ineffective for the aphthous stomatitis. Roflumilast was commenced, resulting in clearance of the oral ulcers. Roflumilast acts by inhibiting PDE4, which in turn increases cyclic adenosine monophosphate, and this causes inflammatory modulators such as interleukins and tumour necrosis factor-α to be downregulated. These inflammatory mediators play a role in oral erosive conditions such as oral lichen planus and recurrent aphthous stomatitis. PDE4 inhibitors, including roflumilast and apremilast, have shown promising results in managing oral ulceration in patients with Behçet disease and aphthous ulcers. We advocate the use of roflumilast for oral erosive conditions when standard systemic agents are ineffective or cause side-effects.

dermatology
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial

Linda Stein Gold,David N. Adam,Lorne Albrecht,Javier Alonso-Llamazares,Laura K. Ferris,Melinda J. Gooderham,H. Chih-ho Hong,Steven E. Kempers,Leon H. Kircik,Mark Lebwohl,Wei Jing Loo,Walter K. Nahm,Kim A. Papp,Daniel Stewart,Darryl P. Toth,Matthew Zirwas,David Krupa,Scott Snyder,Patrick Burnett,Robert Higham,David R. Berk

DOI: https://doi.org/10.1016/j.jaad.2024.03.030

IF: 15.487

2024-03-31

Journal of the American Academy of Dermatology

Abstract:Background Efficacy and/or safety profiles limit topical psoriasis treatments. Objective Evaluate long-term effects of once-daily roflumilast cream 0.3% in patients with psoriasis. Methods In this open-label phase 2 trial, adult patients ( N = 332) with psoriasis who completed the phase 2b parent trial or were newly enrolled applied roflumilast once-daily for 52 weeks. Safety and effectiveness were assessed. Results Overall, 244 patients (73.5%) completed the trial; 13 patients (3.9%) discontinued due to adverse events (AEs) and 3 (0.9%) due to lack of efficacy. Twelve patients (3.6%) reported treatment-related AEs; none were serious. ≥97% of patients had no irritation. No tachyphylaxis was observed with 44.8% of the patients achieving Investigator Global Assessment (IGA) Clear or Almost Clear at Week 52. Limitations Intertriginous-IGA and Psoriasis Area and Severity Index (PASI) were not evaluated in all patients. Conclusions In this long-term trial, once-daily roflumilast cream was well-tolerated and efficacious up to 64 weeks in patients in the earlier trial, suggesting it is suitable for chronic treatment, including the face and intertriginous areas.

dermatology
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

Linda Stein Gold,Javier Alonso-Llamazares,Zoe D Draelos,Melinda J Gooderham,Steven E Kempers,Leon H Kircik,Mark G Lebwohl,Kim A Papp,David M Pariser,Darryl P Toth,Gil Yosipovitch,Robert C Higham,Amy Feng,David R Berk

DOI: https://doi.org/10.1007/s40257-022-00739-3

Abstract:Background: Itch is the most bothersome symptom reported by patients with psoriasis. Safe and effective treatments for psoriasis that also address itch are needed. Objectives: To report effects of roflumilast cream on itch-related outcomes from a Phase 2b trial. Methods: Adults with chronic plaque psoriasis were randomized to roflumilast 0.3%, roflumilast 0.15%, or vehicle once-daily for 12 weeks. Psoriasis severity was assessed via the Investigator Global Assessment (IGA; a 5-point scale assessing plaque thickening, scaling, and erythema ranging from 0 [clear] to 4 [severe]) and ≥ 2 on a modified Psoriasis Area and Severity Index (PASI-HD, which combines severity of lesions and area affected, ranging from 0 [no disease] to 72 [maximal disease], with the actual percentage of the anatomical area involved in those patients with < 10% of anatomical area involved [e.g., 0.1 for 1% to 0.9 for 9%]). Itch was evaluated via Worst Itch Numeric Rating Scale (WI-NRS), Psoriasis Symptom Diary (PSD) Items 1 (severity of itch) and 2 (bother of itch), and itch-related sleep loss NRS scores. Post hoc correlation analyses between WI-NRS and PASI, WI-NRS and itch-related sleep loss, and WI-NRS and DLQI were also performed. Results: Roflumilast-treated patients had significantly greater improvements than vehicle-treated patients in WI-NRS and PSD Items 1 and 2 beginning at Week 2 and in itch-related sleep loss Weeks 6 through 12. Among patients with baseline WI-NRS ≥ 6, significantly more patients achieved ≥ 4-point improvement with roflumilast than with vehicle as early as Week 2. Itch severity had low correlation with PASI while WI-NRS and IGA were not always aligned. Limitations: The first assessment was at 2 weeks, limiting the ability to assess early onset of itch response. Conclusion: Roflumilast cream improved itch and itch-related sleep loss associated with chronic plaque psoriasis. Gov identifier: NCT03638258.
Roflumilast for the Treatment of COPD in an Asian Population

Jinping Zheng,Jinghua Yang,Xiangdong Zhou,Li Zhao,Fuxin Hui,Haoyan Wang,Chunxue Bai,Ping Chen,Huiping Li,Jian Kang,Manja Brose,Frank Richard,Udo-Michael Goehring,Nanshan Zhong

DOI: https://doi.org/10.1378/chest.13-1252

2013-01-01

CHEST Journal

Abstract:Background Roflumilast is the only oral phosphodiesterase 4 inhibitor indicated for use in the treatment of COPD. Previous studies of roflumilast have predominantly involved European and North American populations. A large study was necessary to determine the efficacy and safety of roflumilast in a predominantly ethnic Chinese population. Methods In a placebo-controlled, double-blind, parallel-group, multicenter, phase 3 study, patients of Chinese, Malay, and Indian ethnicity (N = 626) with severe to very severe COPD were randomized 1:1 to receive either roflumilast 500 μg once daily or placebo for 24 weeks. The primary end point was change in prebronchodilator FEV1 from baseline to study end. Results Three hundred thirteen patients were assigned to each treatment. Roflumilast provided a sustained increase over placebo in mean prebronchodilator FEV1 (0.071 L; 95% CI, 0.046, 0.095 L; P < .0001). Similar improvements were observed in the secondary end points of postbronchodilator FEV1 (0.068 L; 95% CI 0.044, 0.092 L; P < .0001) and prebronchodilator and postbronchodilator FVC (0.109 L; 95% CI, 0.061, 0.157 L; P < .0001 and 0.101 L; 95% CI, 0.055, 0.146 L; P < .0001, respectively). The adverse event profile was consistent with previous roflumilast studies. The most frequently reported treatment-related adverse event was diarrhea (6.0% and 1.0% of patients in the roflumilast and placebo groups, respectively). Conclusions Roflumilast plays an important role in lung function improvement and is well tolerated in an Asian population. It provides an optimal treatment choice for patients with severe to very severe COPD. Trial registry ClinicalTrials.gov; No.: NCT01313494; URL: www.clinicaltrials.gov. Roflumilast is the only oral phosphodiesterase 4 inhibitor indicated for use in the treatment of COPD. Previous studies of roflumilast have predominantly involved European and North American populations. A large study was necessary to determine the efficacy and safety of roflumilast in a predominantly ethnic Chinese population. In a placebo-controlled, double-blind, parallel-group, multicenter, phase 3 study, patients of Chinese, Malay, and Indian ethnicity (N = 626) with severe to very severe COPD were randomized 1:1 to receive either roflumilast 500 μg once daily or placebo for 24 weeks. The primary end point was change in prebronchodilator FEV1 from baseline to study end. Three hundred thirteen patients were assigned to each treatment. Roflumilast provided a sustained increase over placebo in mean prebronchodilator FEV1 (0.071 L; 95% CI, 0.046, 0.095 L; P < .0001). Similar improvements were observed in the secondary end points of postbronchodilator FEV1 (0.068 L; 95% CI 0.044, 0.092 L; P < .0001) and prebronchodilator and postbronchodilator FVC (0.109 L; 95% CI, 0.061, 0.157 L; P < .0001 and 0.101 L; 95% CI, 0.055, 0.146 L; P < .0001, respectively). The adverse event profile was consistent with previous roflumilast studies. The most frequently reported treatment-related adverse event was diarrhea (6.0% and 1.0% of patients in the roflumilast and placebo groups, respectively). Roflumilast plays an important role in lung function improvement and is well tolerated in an Asian population. It provides an optimal treatment choice for patients with severe to very severe COPD.
Topical crisaborole is an efficacious steroid‐sparing agent for treating mild‐to‐moderate seborrhoeic dermatitis

S.M. Peña,A.S.W. Oak,A.M. Smith,T.T. Mayo,B.E. Elewski

DOI: https://doi.org/10.1111/jdv.16673

2020-06-17

Journal of the European Academy of Dermatology and Venereology

Abstract:<p>Seborrheic dermatitis (SD) is a common chronic inflammatory condition characterized by flaky, pruritic, erythematous patches in areas of high sebaceous gland concentration. Crisaborole is a topical phosphodiesterase 4 inhibitor currently approved for the treatment of mild to moderate atopic dermatitis. It is generally well‐tolerated, and most common adverse effects include burning/stinging, erythema, and pruritus, all of which are mild and transient.<sup>1</sup> The efficacy and tolerability of topical crisaborole 2% ointment was assessed for facial SD.</p>

dermatology
Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions

Terry M Jones,Iain Stuart

Abstract:BACKGROUND: FMX103 1.5% is the first and only topical minocycline foam that is approved for the treatment of papulopustular rosacea in adults. OBJECTIVE: We sought to characterize the safety and pharmacokinetics of minocycline under maximal-use conditions of FMX103 1.5% in subjects with moderate-to-severe rosacea. METHODS: This Phase Isingle-center, nonrandomized, open-label, single-period pharmacokinetics and safety evaluation study evaluated multiple-dose, topical administration of FMX103 1.5%. Twenty subjects meeting study inclusion/exclusion criteria had ~2 grams of FMX103 1.5% applied to the full face once per day for 14 days. Blood samples were collected 30 minutes prior to study drug application on treatment Days 1, 2, 6, 9, 11, 12, and 14, and also at 2, 4, 8, 12, 16, and 24 hours post-administration on treatment Days 1 and 14. RESULTS: Following topical application of a 2-gram maximal-use dose of FMX103 1.5% for 14 days, minocycline plasma concentrations were low. Overall, trough levels were approximately 0.5ng/mL from 24 hours after the first dose through 24 hours after the last dose on Day 14, indicating that steady-state levels appear to have been reached within the first day of dosing. Daily application of FMX103 1.5% was generally safe and well-tolerated by all subjects. CONCLUSION: Once-daily topical application of FMX103 1.5% did not lead to appreciable systemic exposure or accumulation of minocycline, suggesting that it is a viable treatment option for papulopustular rosacea.
Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema

Zoe Diana Draelos,Robert C Higham,David W Osborne,Melissa S Seal,Patrick Burnett,David R Berk

DOI: https://doi.org/10.36849/JDD.2024.7958

2024-10-01

Abstract:Background: Inflammatory dermatologic conditions suitable for topical treatments benefit from a hydrating vehicle that improves the skin barrier without irritation. Objective: This research was designed to assess skin barrier effects and aesthetic attributes of the vehicle for topical roflumilast cream (vehicle) vs a currently marketed ceramide-containing moisturizing cream (moisturizer). Methods: This was a single-site, randomized, intraindividual, double-blind, controlled study conducted over 17 days. Patients (aged 18 years or older) with mild, symmetric asteatotic eczema of the lower extremities were enrolled to receive lower leg applications of the vehicle on one leg and moisturizer on the other. The primary efficacy endpoint was a change in transepidermal water loss (TEWL) from baseline to day 15. Secondary efficacy endpoints included change from baseline in TEWL at other study visits, change from baseline in hydration as assessed via corneometry, and patient- and investigator-rated assessments of the products. Safety and tolerability were also assessed. Results: A total of 40 patients enrolled in the study. The primary efficacy endpoint was met for both treatments. A statistically significant difference in TEWL on day 1 favored the moisturizer, but no difference was seen between vehicle and moisturizer at any other timepoint. Both vehicle and moisturizer also met the secondary efficacy endpoint of change from baseline in hydration. Limitations: The sample size was small. Conclusions: The vehicle for roflumilast cream performed similarly to a leading, currently marketed, dermatologist-recommended, ceramide-containing moisturizer across all patient- and investigator-rated assessments of efficacy, tolerability, and aesthetic properties in patients with mild asteatotic eczema. J Drugs Dermatol. 2024;23(10):834-840. doi:10.36849/JDD.7958 &nbsp.
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials

huihui zeng,yan chen

IF: 24.3

2014-01-01

European Respiratory Journal

Abstract:Backgroud:This work evaluats the effectiveness of roflumilast, a phosphodiesterase 4 inhibitor, in stable COPD management. Methods: MEDLINE, EMBASE, the Cochrane database, CINAHL, and ClinicalTrials.gov were searched to Dec 2013. Missing data were obtained from authors and manufacturers. Studies were pooled to yield relative risk (RR), odds ratios (OR), weighted mean differences with 95% confidence intervals (CI) with the I 2 statistic. A fixed-effects model (I 2 Results: Ten eligible randomized controlled trials (9574 patients, Jadad score 3) were included. Roflumilast significantly improved pre-bronchodilator(BD) FEV1 (WMD 55.25ml; 95%CI 46.6 to 63.87; p=0.000;I 2 =39.0%), post-BD FEV1 (59.92ml; 51.20 to 68.63; p=0.000; I 2 =15.5%), and post-BD FVC (58.3ml; 43.7 to 72.9; p=0.000; I 2 =0.0%). The improvement on lung function was greater in Asian population than other population. Roflumilast was associated with prolonged median time to first exacerbation (HR: 0.86; 95%CI: 0.78 to 0.95; p=0.02; I 2 =13.9%) and reduction in exacerbations (RR:0.85; 95%CI: 0.79 to 0.91; p=0.000; I 2 =0.0%). The improvement in SGRQ score or transition dyspnea index score was statistically but not clinically significant (WMD:-1.57;95%CI -2.49 to -0.65; p=0.001; I 2 =47.0%, and 0.27;0.14 to 0.39; p=0.000;I 2 =29.9%, respectively). Roflumilast did not affect all-cause mortality, but increased some adverse events including diarrhea, nausea, and weight loss. Weight loss was most evident in obese patients (BMI>30). Conclusion:Roflumilast improved lung function and reduce mean exacerbation rate in stable COPD patients with a high risk of adverse events and variaty in different COPD phenotypes.
[Phosphodiesterase 4 inhibitors in dermatology : Role in the treatment of skin diseases]

Morna F Schmidt,Nicole Albuscheit,Amir S Yazdi

DOI: https://doi.org/10.1007/s00105-024-05407-7

2024-08-30

Abstract:Background: Chronic inflammatory skin diseases are of great social and medical importance and require effective drug therapy. Phosphodiesterase 4 (PDE4) inhibitors represent a possible therapeutic option by regulating inflammatory processes. PDEs cause the release of proinflammatory cytokines by interfering with signaling pathways. The PDE4 inhibitors apremilast (treatment of psoriasis and Behçet's disease), roflumilast (treatment of chronic obstructive pulmonary disease), and crisaborole (treatment of atopic dermatitis) are currently approved in Europe. Psoriasis: Apremilast is used for second-line treatment of plaque psoriasis and psoriatic arthritis and has a favorable side effect profile. Topical PDE4 inhibitors are currently being researched and have not yet been approved by the European Medicines Agency (EMA). Atopic dermatitis: The topical PDE4 inhibitor crisaborole was approved by the EMA in 2020 as a topical treatment alternative to glucocorticoids and calcineurin inhibitors. Although the substance has shown good tolerability in studies and also alleviates the accompanying itching, it did not find its way onto the German market. BEHçET'S DISEASE: Apremilast is approved for the treatment of Behçet's disease in adults with refractory, severe oral ulcers. Outlook: Case studies have also demonstrated the efficacy of systemic PDE4 inhibition in other skin diseases (including blistering autoimmune dermatoses, lichen planus, and acantholytic genodermatoses). The substances are also being researched and used to treat extracutaneous inflammatory diseases.
Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases

Jonathan E. Phillips

DOI: https://doi.org/10.3389/fphar.2020.00259

IF: 5.6

2020-03-12

Frontiers in Pharmacology

Abstract:PDE4 inhibitors can suppress a variety of inflammatory cell functions that contribute to their anti-inflammatory actions in respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. The systemically delivered PDE4 inhibitor roflumilast has been approved for use in a subset of patients with severe COPD with chronic bronchitis and a history of exacerbations. Use of systemically delivered PDE4 inhibitors has been limited by systemic side effects. Inhaled PDE4 inhibitors have been considered as a viable alternative to increase tolerability and determine the maximum therapeutic potential of PDE4 inhibition in respiratory diseases.

pharmacology & pharmacy

Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

Research progress of roflumilast in the treatment of chronic obstructive pulmonary disease

639 - Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial

Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials

Successful Treatment of Seborrheic Dermatitis with Topical Roflumilast: A Case Series

505 - Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials

504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)

Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors

Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

P099 Use of roflumilast in erosive oral inflammatory conditions

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

Roflumilast for the Treatment of COPD in an Asian Population

Topical crisaborole is an efficacious steroid‐sparing agent for treating mild‐to‐moderate seborrhoeic dermatitis

Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions

Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema

Roflumilast for stable COPD: Meta-analysis of randomized controlled trials

[Phosphodiesterase 4 inhibitors in dermatology : Role in the treatment of skin diseases]

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases